CK Life Sciences, the biotech arm of Hong Kong billionaire Li Ka-shing, has agreed to merge a Canadian drug development unit, WEX Pharmaceuticals, with Nasdaq-listed Virios Therapeutics.
关于我们
Tungsten Advisors (www.tungstenadv.com) is an investment banking firm focused on strategic advisory and corporate finance for healthcare and technology companies. Tungsten provides transactional services including financings (private placements/PIPEs), corporate licensing and mergers and acquisitions (M&A). Tungsten also focuses on company incubation and makes direct investments alongside the creation of new companies in healthcare and technology. Securities offered through Finalis Securities LLC Member FINRA/SIPC. Tungsten Partners LLC d/b/a Tungsten Advisors and Finalis Securities LLC are separate, unaffiliated entities.
- 网站
-
https://www.tungstenadv.com
Tungsten Advisors的外部链接
- 所属行业
- 投资银行业务
- 规模
- 2-10 人
- 总部
- New York，New York
- 类型
- 私人持股
- 创立
- 2019
地点
-
主要
获取路线
767 3rd Ave
US，New York，New York，10017
Tungsten Advisors员工
动态
-
Virios Therapeutics?Acquires WEX Pharmaceuticals Inc. for $100 Million to form Dogwood Therapeutics and Concurrently Completes a $19.5?Million Financing.?Tungsten Advisors?served as the exclusive financial advisor and placement agent to Virios Therapeutics. Read more: https://lnkd.in/efnuHDSk Learn more about our transactions: https://lnkd.in/emFVn-KR
Virios Therapeutics Acquires Wex Pharmaceuticals for $100 Million to form Dogwood Therapeutics and Concurrently Completes a $19.5 Million Financing
tungstenadv.com
-
Onconetix Completes Up to $27 Million Equity Financing.?Tungsten Advisors served as the financial advisor to Onconetix. Read more:?https://lnkd.in/eBG5PEG7 Learn more about our transactions: https://lnkd.in/emFVn-KR
Onconetix Completes Up to $27 Million Equity Financing
tungstenadv.com
-
BioAtla, Inc. Completes Outward Global License of BA3362 to Context Therapeutics for Up to $133.5 Million Plus Royalties.?Tungsten Advisors?served as the exclusive financial advisor to BioAtla. Read more:?https://lnkd.in/ecwr_Grj Learn more about our transactions: https://lnkd.in/emFVn-KR
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
tungstenadv.com
-
This morning, Context Therapeutics announced the licensing of CT-202, a Nectin-4 x CD3 TCE, from BioAtla, Inc.. This marks Context's 2nd asset transaction in 2024. I want to thank the tireless efforts of the Context and BioAtla teams, as well as our respective external advisors from Tungsten Advisors, Piper Sandler, Goodwin, and Orrick, Herrington & Sutcliffe LLP. Special thanks to Alex Levit, Bill Boyle, Eric Butz, Daniel Scolnick, Ph.D., Esq., Blake O'Shaughnessy, and Romy Seth.
Context Therapeutics and BioAtla, Inc. Announce Exclusive Worldwide License Agreement to Develop and Commercialize CT-202 (formerly BA3362), a Nectin-4 x CD3 T Cell Engaging Antibody. - Context to obtain exclusive development and commercialization rights to CT-202 - BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales - Context anticipated IND filing for CT-202 in mid-2026 https://lnkd.in/eH2H2Whi
-
-
MolecuLight Completes a $11.7?Million Financing.?Tungsten Advisors?served as the exclusive financial advisor to MolecuLight. Read more: https://lnkd.in/e5ZcEYCY Learn more about our transactions: https://lnkd.in/emFVn-KR
MolecuLight Secures $11.7 Million in Financing to Accelerate Global Expansion
tungstenadv.com
-
Onconova Therapeutics Acquires Trawsfynydd Therapeutics for $100 Million to form Traws Pharma and Concurrently Completes a $14?Million Financing led by OrbiMed and Torrey Pines. Tungsten Advisors served as the exclusive financial advisor and placement agent to Onconova.
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
finance.yahoo.com
-
First Wave BioPharma, Inc.?Completes Acquisition of ImmunogenX for $95 Million, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline.?Tungsten Advisors?served as the exclusive financial advisor to First Wave BioPharma.
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
globenewswire.com
-
First Wave BioPharma, Inc. Enters into Term Sheet to Acquire ImmunogenX for $95 Million?and Establish a Leading Late-Stage GI-Focused Biopharmaceutical Company. Tungsten Advisors served as the exclusive financial advisor to First Wave BioPharma.
First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company
globenewswire.com
-
Proteomedix AG?Acquired by Blue Water Biotech for $75 Million?to form Onconetix, a Commercial Stage Men’s Health Pharma and Diagnostics Company. Tungsten Advisors served as the exclusive financial advisor to Proteomedix.
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix?
globenewswire.com